Healthcare
XORTX Therapeutics Inc.(XRTX)
Live Price
Offline$2.18
+0.00% today
1Y Change
-48.71%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +50.6%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
XORTX Therapeutics Inc. (XRTX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.18 and down 48.7% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.6%, free cash flow +23.2% with operating margin 0.0% and ROIC -121.0%. Stock Foundry combines XRTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +50.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +28.9% | +14.9% | โ |
2026 Feb 26, 2026 | +89.2% | +1.5% | +7.7% | -14.6% |
2025 Nov 14, 2025 | +22.2% | -3.8% | -0.7% | +7.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XRTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XRTX Max Drawdown
-68.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XRTX and SPY.
Company Overview
XORTX Therapeutics Inc.
NASDAQ Capital Market
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
- Leadership
- Allen Warren Davidoff
- IPO Date
- Sep 23, 2021
- Employees
- 2
- Street Address
- 421 โ 7th Avenue SW
- Mailing
- Vancouver, BC, T2P 4K9
- Region
- Vancouver, BC, CA
- Reporting Currency
- USD
- Investor Line
- +1 403 455 7727
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- โ
- Price/Book
- 0.3
Growth
- Revenue
- 0.0%
- EPS
- +50.6%
- Free Cash Flow
- +23.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -111.1%
- ROIC
- -121.0%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 1.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.